{
  "docId": "019de072-ef20-75e9-922b-a59946a49f08",
  "docSlug": "b6265fe9aad535c251b3bd786fc797fa",
  "documentTitle": "BioAtla | Investor Conference Presentation Deck | 15 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 15,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "other",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a tree-like structure to map study arms to specific patient cohorts and their corresponding interim outcomes.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-ef20-75e9-922b-a59946a49f08/8",
  "deckHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08",
  "deckJsonHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08.json",
  "deckAnchorHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.78,
        "y": 0.0034
      },
      "kind": "callout",
      "text": "Interim results satisfied pre-defined 'Go' criteria into part 2 of the Phase 2 BA3011 study in both UPS and Osteosarcoma",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b711a9a0-0b70-4363-8923-b1e9b5374657",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.75,
        "x": 0.03,
        "y": 0.0017
      },
      "kind": "diagram",
      "text": "Flowchart showing study arms (Monotherapy, Combination) branching into disease types and then into specific interim results.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7ca0703-1734-45c9-a47c-7ac4e496246b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.1,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Pre-defined criteria for each subgroup up to 10 patients: 'No Go' if 0 CR/PR and PFS rate at 12 weeks <40%; 'Go' if ≥1 CR/PR or PFS rate at 12 weeks ≥40%. * As of data cut-off of Apr 28, 2022; Cohorts in grey continuing enrollment until sufficient sample size is achieved. **Included in UPS cohort. BA3011 dose 1.8 mg/kg Q2W. Inclusion criteria: measurable disease, ECOG performance status 0 or 1. PFS, progression-free survival; PR, partial response; UPS, undifferentiated pleomorphic sarcoma.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfb51152-65ad-48b8-9b46-885a2570eda1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Sarcoma: Encouraging Phase 2 Part 1 Topline Interim Analysis Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbf69e43-53a2-4b52-b7de-3f6a95658c67",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 8,
      "beatId": "a2f0c948-598d-4d79-b3c7-468643785781",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The deck agitates the problem on slide 8 with encouraging Phase 2 Part 1 Topline Interim Analysis Results",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f124c2ae-e161-40d9-ad82-028c83aa9dba",
      "evidence": "The deck presents a problem statement and agitates it with encouraging Phase 2 Part 1 Topline Interim Analysis Results",
      "position": 0,
      "objective": "What are the consequences of not improving cancer therapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}